Burnett Patrick's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 6, 2023
- Accession no.
- 0001567619-23-004541
- Filed
- Mar 6, 2023
- Trade date
- Mar 2, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $27.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burnett PatrickCIK 0001741987 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Common Stock | SSaleDisposed | −1,728 | $15.82F2 | −$27,336.96 | 39,836 | Direct | |
| Mar 2, 2023 | Common Stock | SSaleDisposed | −23 | $16.52 | −$379.96 | 39,813 | Direct | |
| Mar 2, 2023 | Common Stock | AGrant or awardAcquired | +21,000 | $0.00 | $0 | 60,813 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Common Stock | AGrant or awardAcquired | +55,800 | $0.00 | $0 | 55,800 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Reporting Person's title: Senior Vice President and Chief Medical Officer